Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Bevacizumab with Chemotherapy in Advanced NSCLC
NCT00368992Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Aug 2006; status: completed.
02
Drugs
KL-140bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00368992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368992.